Sumii T, Singhal A B, Asahi M, Shimizu-Sasamata M, Suzuki M, Miyata K, Lo E H
Department of Neurology, Massachusetts General Hospital, Charlestown 02129, USA.
Neuroreport. 2001 Mar 5;12(3):615-8. doi: 10.1097/00001756-200103050-00037.
The effects of alteplase (tissue plasminogen activator, t-PA) and pamiteplase (a modified t-PA with longer half-life and increased potency) were compared in a clinically relevant model of embolic stroke. Rats were treated with pamiteplase (0.5 mg/kg or 1 mg/kg bolus), alteplase (10 mg/kg infusion) or normal saline. Pamiteplase (1 mg/kg) was as effective as alteplase in reducing 24 h brain infarct volumes, neurological deficit scores and residual clot grades. Cerebral blood flow recovery at 30 min after thrombolytic treatment was partial and did not correlate with 24 h infarct volumes or neurological deficits. However, there was good correlation between 24 h residual clot grades and infarct volumes, suggesting a delayed timeframe for pamiteplase- and alteplase-induced reperfusion.
在一个临床相关的栓塞性中风模型中，比较了阿替普酶（组织型纤溶酶原激活剂，t-PA）和帕米普酶（一种半衰期更长、效力增强的改良型t-PA）的效果。给大鼠分别注射帕米普酶（0.5毫克/千克或1毫克/千克推注剂量）、阿替普酶（10毫克/千克输注剂量）或生理盐水。帕米普酶（1毫克/千克）在减少24小时脑梗死体积、神经功能缺损评分和残余血栓等级方面与阿替普酶效果相当。溶栓治疗后30分钟时脑血流的恢复是部分性的，且与24小时梗死体积或神经功能缺损无关。然而，24小时残余血栓等级与梗死体积之间存在良好的相关性，提示帕米普酶和阿替普酶诱导再灌注的时间框架有所延迟。
